Physician profile
Ronald Mark Harris
NPI 1215033501
$13,962.75
in general payments reported to CMS, 2019-2025
34 companies · $2,871 in 2025
The $2,871 reported for 2025 was more than what 91% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,709 · 2020: $486 · 2021: $836 · 2022: $574 · 2023: $977 · 2024: $1,508 · 2025: $2,871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,264 · Education: $93.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,263.55 |
| Education | $93.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $6,242.49 | 2019 | |
| Abbvie INC. | $1,008.63 | 2019-2025 | |
| Genzyme Corporation | $773.66 | 2020-2025 | |
| Janssen Biotech, INC. | $729.35 | 2020-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $720.26 | 2021-2025 | Libtayo, Dupixent |
| Amgen INC. | $501.75 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $498.65 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $390.56 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $358.87 | 2024-2025 | Zoryve |
| Janssen Scientific Affairs, LLC | $298.59 | 2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $297.97 | 2022-2025 | Sotyktu |
| Ucb, INC. | $297.82 | 2024-2025 | Bimzelx |
| Merz North America, INC. | $240.54 | 2025 | |
| Lilly USA, LLC | $214.98 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $189.61 | 2021-2024 | Adbry |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prugen, INC. Pharmaceuticals | $177.12 | 2019-2020 | |
| Pfizer INC. | $172.20 | 2020-2025 | |
| Dermavant Sciences, INC. | $169.36 | 2023-2024 | Vtama |
| Journey Medical Corporation | $114.11 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.84 | 2023-2025 | Spevigo |
| Incyte Corporation | $99.27 | 2024-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $73.22 | 2025 | Cabtreo |
| Mayne Pharma Commercial LLC | $55.02 | 2025 | |
| Galderma Laboratories, L.P. | $45.68 | 2021-2023 | |
| Organogenesis INC. | $34.68 | 2023-2024 | Puraply |
| Helsinn Therapeutics (U.S.), INC. | $28.42 | 2021-2023 | Valchlor |
| Biofrontera INC. | $24.77 | 2019-2020 | |
| Springworks Therapeutics, INC. | $24.77 | 2025 | Gomekli |
| Verrica Pharmaceuticals INC. | $23.11 | 2023 | Ycanth |
| Organon LLC | $18.20 | 2025 | Hadlima |
| Celgene Corporation | $15.16 | 2019 | |
| Botanix Sb INC | $14.09 | 2025 | Sofdra |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.